Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) With and Without Low-Dose Cyclophosphamide in Advanced Stage Non-Small Cell Lung Cancer
Conditions
Interventions
CG8123
Cyclophosphamide
Start Date
March 1, 2003
Completion Date
January 1, 2006
Last Updated
December 24, 2007
NCT06066138
NCT05692635
NCT07485114
NCT06305754
NCT05198830
NCT06498635
Lead Sponsor
Cell Genesys
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions